Artiva Biotherapeutics (ARTV) Enterprise Value (2023 - 2025)
Artiva Biotherapeutics (ARTV) has disclosed Enterprise Value for 3 consecutive years, with -$108.0 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 41.75% to -$108.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$108.0 million, a 41.75% increase, with the full-year FY2025 number at -$108.0 million, up 41.75% from a year prior.
- Enterprise Value was -$108.0 million for Q4 2025 at Artiva Biotherapeutics, up from -$220.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $50.2 million in Q2 2024 to a low of -$220.5 million in Q3 2025.
- A 3-year average of -$94.9 million and a median of -$108.0 million in 2025 define the central range for Enterprise Value.
- Biggest YoY gain for Enterprise Value was 193.53% in 2024; the steepest drop was 534.51% in 2024.
- Artiva Biotherapeutics' Enterprise Value stood at $42.7 million in 2023, then tumbled by 534.51% to -$185.4 million in 2024, then skyrocketed by 41.75% to -$108.0 million in 2025.
- Per Business Quant, the three most recent readings for ARTV's Enterprise Value are -$108.0 million (Q4 2025), -$220.5 million (Q3 2025), and -$142.4 million (Q2 2025).